AKTS
Aktis Oncology, Inc.
18.20$
+2.3%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -83.0% | +12,113.5% | +47.7% | -36.0% | -37.4% | +14.4% | +58.8% | -26.5% | +185.8% | -20.0% | -4.6% | -29.9% | +0.8% | +73.8% | +105.7% | +92.4% | -14.3% | -13.4% | +96.6% | +25.5% | +13.0% | +7.0% | +5.4% | +25.4% | +13.3% | -16.0% | +0.2% | +7.0% | +20.2% | -89.7% | +55.1% | +10.6% | -1.4% | +18.4% | +72.6% | +4.9% | – | |
| – | – | – | – | – | – | +70.7% | -6.5% | -39.0% | -23.5% | +157.2% | -19.1% | -33.3% | +68.2% | +134.2% | -72.4% | +394.9% | +53.5% | +57.8% | +14.3% | +15.3% | -15.3% | +56.8% | +18.0% | +24.1% | -3.2% | -18.3% | +60.6% | +18.5% | -19.4% | -21.6% | +13.0% | -34.0% | – | – | – | – | – | – | +34.8% | – | |
| – | – | – | – | -83.0% | +4,271.4% | +6.5% | -120.8% | – | – | -178.2% | – | – | -56.8% | -230.0% | – | -584.9% | – | – | – | – | – | – | – | – | – | – | -288.8% | – | – | – | -48.8% | +1,132.7% | -78.3% | – | – | – | +18.4% | +37.7% | -2.7% | – | |
| – | -8.0% | +18.9% | +49.8% | +57.9% | +63.7% | +15.6% | -12.3% | +23.0% | +17.7% | +2.6% | +22.7% | -14.0% | +6.5% | -3.6% | +17.8% | -17.0% | +33.3% | -12.8% | -6.1% | +32.2% | +15.5% | +15.3% | -9.6% | +23.0% | -1.3% | -24.3% | -3.9% | +11.1% | +26.7% | -38.0% | -6.9% | -54.9% | +367.9% | +25.8% | +17.4% | -11.6% | +0.2% | +21.5% | +26.2% | – | |
| – | +30.4% | +63.6% | -41.8% | +23.4% | +23.4% | +19.5% | +11.5% | -4.2% | +5.1% | -27.4% | +37.8% | -18.9% | +40.4% | -1.5% | -6.2% | +5.6% | +7.1% | +14.8% | +1.0% | +6.1% | +7.6% | +32.8% | +11.2% | +4.3% | +17.0% | -16.4% | +51.0% | -8.6% | +26.9% | -9.1% | -3.9% | -22.3% | -43.2% | -15.1% | +10.0% | -16.8% | -18.0% | +112.8% | +19.9% | – | |
| – | +14.2% | +40.1% | -22.8% | +59.5% | +46.4% | +17.1% | -3.1% | +10.9% | +11.0% | -6.6% | +26.9% | -14.1% | +14.6% | -2.8% | +9.2% | -10.0% | +23.8% | -4.1% | -3.4% | +21.9% | +12.8% | +21.0% | -2.1% | +15.4% | +5.5% | -21.1% | +19.9% | +0.4% | +26.8% | -23.7% | +0.6% | -39.0% | +71.9% | +18.2% | +15.2% | -12.3% | -2.7% | +31.4% | +24.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +45.7% | – | – | – | +13.0% | +10.9% | +5.4% | +13.1% | +8.9% | +19.0% | +19.0% | – | – | – | – | – | +350.3% | -5.5% | -27.4% | -28.0% | +32.2% | +40.0% | +9.7% | -4.3% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -320.7% | – | – | – | -236,500.0% | – | – | +100.0% | +0.0% | -50.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.